GUIDE: A Randomized Non-Comparative Phase II Trial of Biomarker-Driven Intermittent Docetaxel Versus Standard-of-care Docetaxel in Metastatic Castration-Resistant Prostate Cancer (ANZUP 1903).
JOURNAL OF CLINICAL ONCOLOGY(2023)
关键词
Metastatic Prostate Cancer
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要